In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU. Shots: The funding will extend the …
In an interview with PharmaShots, Mari Mitrani, Chief Science Officer of Organicell shares her views on the positive results from the first ten COVID-19 patients treated with Zofin in India. Shots: This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, which has entered into a product testing and distribution agreement …
Kaia Health has raised a further $75m to expand its AI-based treatment for Musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD). The company’s technology is based on motion-capture technology that can be used on an everyday smartphone to give feedback about exercises and physical therapy. Kaia said that the pandemic has accelerated demand and says …
Kaia Health raises $75m for digital musculoskeletal disease therapy Read More »
Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care. Founder and CEO Konstantin Mehl spoke to pharmaphorum’s news editor Richard Staines about why these treatments will be in demand as the world emerges from the pandemic. To say that …
Kaia Health gets $75m for digital solution to strains and pains of pandemic workplace Read More »
What You Should Know: – Digital therapeutics company, Kaia Health, has raised $75M Series C round (total: $125M) to expand clinical capabilities and transform the treatment path for Musculoskeletal (MSK) and Chronic obstructive pulmonary disease (COPD) care in the U.S. and Europe. – The Series C round was led by an unnamed leading growth equity fund with support from …
Digital Therapeutics Startup Kaia Health Raises $75M to Optimize MSK & COPD Care Read More »
Shares in Hikma have rallied as it resumed the launch of its generic Advair Diskus in the US, after clearing up a final piece of bureaucracy with the FDA. The London-listed firm is one of several companies that had been trying to make generics of GlaxoSmithKline’s former respiratory diseases blockbuster for the US market. Advair …
Hikma shares rally after US launch of Advair generic resumes Read More »
A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West Virginia has decided in favour of AZ in litigation against Mylan Pharmaceuticals and Kindeva, the company said in a statement. Mylan, which is now part of …
AstraZeneca breathes sigh of relief as court blocks US Symbicort generic Read More »
What You Should Know: – Highmark Health has engaged Verily to build out digital health tools for patients and analytics solutions for Highmark’s clinicians as part of its Living Health model. This marks the first collaboration of its kind for Verily, Google Cloud and a partner. – Highmark Health is a Blue Cross Blue Shield health plan based in …
Highmark Health Taps Verily to Build Digital Health Tools for Living Health Model Read More »
UK-based Verona Pharma has scored a new win with its chronic obstructive pulmonary disease (COPD) drug ensifenitrine, after a formulation delivered with an inhaler met its goals in a phase 2 trial. The company has been making slow but steady progress with ensifentrine and finally began to make a case for the potential first-in-class drug …
Boost for Verona Pharma after trial win with inhaled COPD drug Read More »
In a recent interview with PharmaShots, Jonas Duss, US CEO and Co-Founder at Kaia Health shared his views on the Kaia Health’s COPD Pulmonary Rehabilitation App and their collaboration with Chiesi Group to commercialize the app in EU. Shots: Kaia Health signs an exclusive agreement with Chiesi Group to commercialize the Kaia Health COPD Pulmonary …
In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs. Shots: Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which …
What You Should Know: – Wolters Kluwer, Health launches new Alexa skill, Emmi Care Plan to keep patients engaged with their care team at home following discharge from the hospital. – Using a natural dialogue that automatically adjusts to patient responses, customers can engage with the skill on Alexa-enabled devices simply by saying, “Alexa, ask …
In the first episode of our Health Innovators series, Paul Tunnah speaks to David Van Sickle, CEO of Propeller Health about how digital technologies are revolutionising the field of respiratory medicine. The post Health Innovators: David Van Sickle on digital innovation in respiratory medicine appeared first on .
What You Should Know: – Apstar Pharma acquires the assets of respiratory health company Cohero Health to expands its digital portfolio with a focus on respiratory disease management. – Cohero Health develops digital tools and technologies to improve respiratory care, reduce avoidable costs, and optimize medication utilization. AptarGroup, Inc., a global leader in consumer dispensing, …
Aptar Pharma Acquires the Assets of Respiratory Startup Cohero Health Read More »
What You Should Know: – Mayo Clinic announced a collaboration with Vocalis Health to to research and develop new voice-based tools for screening, detecting and monitoring patient health, beginning with a study to identify vocal biomarkers to detect pulmonary hypertension (PH). – The clinical validation study will utilize Vocalis Health’s proprietary software, which can operate …
Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection Read More »
Eric Tran, Tulane School of Medicine Donald Voltz, MD, Aultman Hospital The COVID-19 virus is ravaging the planet at a scale not seen since the infamous Spanish Flu of the early 1900s, inflicting immense devastation as the U.S. loses more than 200,000 lives and counting. According to CDC statistics, 94% of patient mortalities associated with …
Rural Hospital Execs Can Beat COVID-19 By Shifting From Reactive to Proactive Care Read More »
What You Should Know: – Today, Blue Cross and Blue Shield of North Carolina partners with Carrot Inc. and Virta Health to help address two of the largest ongoing health issues facing Americans today – smoking and type 2 diabetes. – Virta and Carrot’s programs will be available to individual under-65 members and fully insured …
Blue Cross NC Launches No-Cost Virtual Programs to Quit Smoking and Reverse Diabetes Read More »
Shots: The CHMP’s positive opinion is based on P-III ETHOS & KRONOS studies, which are a part of AstraZeneca’s P-III ATHENA program assessing Trixeo Aerosphere in 15500+ patients globally across 11 trials P-III ETHOS study results reported that triple-combination therapy showed a reduction in the rate of moderate or severe exacerbations compared with the Bevespi …
AireHealth, which makes portable nebulizers for patients with respiratory conditions, plans to launch its first connected product next year.
Verona Pharma is to develop its lung drug ensifentrine for patients with COVID-19, joining the legions of drug companies repurposing their medicines to fight the pandemic. Based in the UK and US, Verona is due to start a phase 3 trial of ensifentrine in chronic obstructive pulmonary disease (COPD) later this year after encouraging results …
Verona Pharma to trial lung drug ensifentrine for COVID-19 Read More »
What You Should Know: – Innovaccer has recently partnered with CareSignal to address healthcare’s urgent need amidst the COVID-19 pandemic: to create and maintain solid, clinically actionable relationships with patients in a new set of predominantly virtual care. – CareSignal offers evidence-based end-to-end support services for chronic medical conditions such as asthma, CHF, COPD, diabetes, …
Innovaccer, CareSignal Partner to Enable Deviceless Remote Patient Monitoring Read More »
Shots: The approval is based on P-III ETHOS study assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] with mod. to sev. COPD and a history of exacerbation(s) in the previous year The P-III ETHOS study demonstrated a reduction in the rate of moderate or severe exacerbations. …
AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the US following a rejection last year. Approval follows a rejection by the FDA in October last year after the FDA refused to grant a licence based on findings of the KRONOS clinical trial and asked for further …
Teva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to a phone to help manage asthma and COPD symptoms. Israel-based Teva said the system conveys information to patients, who can use the product branded as ProAir Digihaler (albuterol sulfate) for patients with asthma and chronic obstructive pulmonary disease (COPD). Teva noted …
Teva launches digital asthma and COPD rescue inhaler in US Read More »
What You Should Know: – Propeller Health announced it will co-package a new asthma medication from Novartis, which was approved by the European Commission this week for use in the EU. – Enerzair® Breezhaler® plus Propeller Health sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform. – Propeller’s …
Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription Read More »
<div class="right-align"> <a class="btn btn-blue _gt" data-category="Hospital" data-action="Click-Button" data-label="Blog-Reducing Respiratory Failure Readmissions While COPD Is on the Rise" href="https://www.kindredhealthcare.com/docs/default-source/default-document-library/kindred-respiratory-failure-whitepaper.pdf?sfvrsn=74f58dea_2" title="Reducing Respiratory Failure Readmissions While COPD Is on the Rise" target="_blank">Download this article as a PDF</a></div> <br /> <p>Diagnoses of Chronic Obstructive Pulmonary Disease (COPD) have been on the rise since the early 2000s. By 2030, …
Reducing Respiratory Failure Readmissions While COPD Is on the Rise Read More »
English
Afrikaans
Shqip
አማርኛ
العربية
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
简体中文
繁體中文
Corsu
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Filipino
Suomi
Français
Frysk
Galego
ქართული
Deutsch
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
हिन्दी
Hmong
Magyar
Íslenska
Igbo
Bahasa Indonesia
Gaelige
Italiano
日本語
Basa Jawa
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
한국어
كوردی
Кыргызча
ພາສາລາວ
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Bahasa Melayu
മലയാളം
Maltese
Te Reo Māori
मराठी
Монгол
ဗမာစာ
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
سنڌي
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
O‘zbekcha
Tiếng Việt
Cymraeg
isiXhosa
יידיש
Yorùbá
Zulu